AUG 30 2026
Pfizer — Comirnaty (Comirnaty) $PFE
for COVID-19
FDA approved Pfizer and BioNTech's updated Comirnaty COVID-19 vaccine targeting the XFG variant.
About
COVID-19 is a contagious disease caused by the SARS-CoV-2 virus, which led to a global pandemic. Comirnaty is a vaccine that teaches the body's immune system to recognize and fight the virus. This updated vaccine targets a specific variant, potentially helping to protect against severe illness.
Pivotal trial
Despite the greater risk of adverse COVID-19 outcomes, antibody and cell-mediated immune responses to COVID-19 vaccines vary amongst immunocompromised (IC) people and are poorly defined. IC hosts were largely excluded from the COVID-19 vaccine registration trials, though many countries recommend additional and booster doses of vaccination in this group
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Comirnaty
- BioNTech's Gotistobart Extends Survival to 18.5 Months, but Comirnaty's Slide Keeps the Stock Under - AD HOC NEWS
- BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More (BNTX) - Seeking Alpha
- Arbutus takes Comirnaty LNP patent fight to Canada and UPC - Life Sciences IP Review
- COVID-19 vaccination: FDA narrows COMIRNATY use to older adults and high-risk patients - Vera Health
- Close-up of a COVID-19 vaccine vial labeled Comirnaty beside a syringe, with additional vials and packaging blurred in the background. Photo from LA Times article not for re-use. - UCLA